Mereo BioPharma Group (MREO) Stock Price Target 2026

The average analyst price target for Mereo BioPharma Group is $4.58, 1434.3% above the current price. Of 8 analysts, 5 rate it Buy, 2 Hold and 1 Sell. Targets range from $0.50 to $8. The latest change came on Aug 19, 2026, when JP Morgan downgraded Mereo BioPharma Group from Neutral to Underweight.

The Average Analyst Price Target for Mereo BioPharma Group is $4.58.

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

5Buy

2Hold

1Sell

Consensus RatingOutperform# Analysts8Avg. Consensus PT$4.58Upside to Avg. PT+1434.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Mereo BioPharma Group Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 10, 2026	BTIG	Julian Harrison	Maintained	Buy	$1
Aug 19, 2026	JP Morgan	Priyanka Grover	Downgrade	Neutral→Underweight	—
Aug 11, 2026	BTIG	Julian Harrison	Maintained	Buy	$1
Aug 11, 2026	Needham	Gil Blum	Maintained	Buy	$3
May 12, 2026	BTIG	Julian Harrison	Maintained	Buy	$1
Mar 23, 2026	JP Morgan	Priyanka Grover	Downgrade	Overweight→Neutral	—
Jan 16, 2026	BTIG	Julian Harrison	Maintained	Buy	$1
Jan 13, 2026	Needham	Gil Blum	PT Cut	Buy	$5→$3
Dec 30, 2025	Jefferies	Maury Raycroft	Downgrade	Buy→Hold	$7→$1
Dec 29, 2025	BTIG	Julian Harrison	PT Cut	Buy	$6→$1
Dec 29, 2025	LifeSci Capital	Cory Jubinville	Downgrade	Outperform→Market Perform	—
Dec 22, 2025	Needham	Gil Blum	Maintained	Buy	$5
Dec 18, 2025	BTIG	Julian Harrison	Maintained	Buy	$6
Aug 25, 2025	JP Morgan	Priyanka Grover	PT Raise	Overweight	$7→$8
Jul 10, 2025	Needham	Gil Blum	PT Cut	Buy	$7→$5
May 13, 2025	Needham	Gil Blum	Maintained	Buy	$7
Apr 9, 2025	Needham	Gil Blum	Maintained	Buy	$7
Mar 27, 2025	JP Morgan	Priyanka Grover	Initiate	Overweight	$7
Mar 26, 2025	Needham	Gil Blum	Maintained	Buy	$7
Mar 18, 2025	Cantor Fitzgerald	Kristen Kluska	Maintained	Overweight	$7